635-79-0Relevant articles and documents
COMPOSITIONS AND METHODS FOR TREATING MUSCULAR DYSTROPHIES
-
Page/Page column 44; 59, (2022/04/03)
The present disclosure relates to compounds that increase sarcospan expression. The disclosure further relates to methods of treating a disease related to diminution or dysfunction of a dystrophin-related complex in a subject in need thereof.
Quinoline- and 1,8-naphthyridine-3-carboxylic acids using a self-catalyzed Friedl?nder approach
Nammalwar, Baskar,Murie, Maeghan,Fortenberry, Chelsea,Bunce, Richard A.
supporting information, p. 3181 - 3183 (2014/05/20)
One-step syntheses of 2-alkyl- and 2,4-dialkyl-substituted quinoline-3-carboxylic acids and 1,8-naphthyridine-3-carboxylic acids are reported using a catalyst-free Friedl?nder reaction. The reaction is carried out in one step by simple heating of 2-aminobenzaldehyde, 2-amino-5-chlorobenzaldehyde, 2-aminonicotinaldehyde, or 2-aminoacetophenone with a β-ketoester in toluene or xylene for 24 h. Under these conditions, the carboxylic acid product is isolated directly from the reaction mixture without need for further purification. The observation that the reaction starts slowly and accelerates as it proceeds suggests that the transformation is self-catalyzed. This hypothesis is also supported by the finding that attempts to extend the current reaction to diketones, which cannot hydrolyze to an acid, were generally unsuccessful.
Small-molecule inhibitors of histone acetyltransferase activity: Identification and biological properties
Mai, Antonello,Rotili, Dante,Tarantino, Domenico,Ornaghi, Prisca,Tosi, Federica,Vicidomini, Caterina,Sbardella, Gianluca,Nebbioso, Angela,Miceli, Marco,Altucci, Lucia,Filetici, Patrizia
, p. 6897 - 6907 (2007/10/03)
Starting from a yeast phenotypic screening performed on 21 compounds, we described the identification of two small molecules (9 and 18) able to significantly reduce the S. cerevisiae cell growth, thus miming the effect of GCN5 deletion mutant. Tested on a GCN5-dependent gene transcription assay, compounds 9 and 18 gave a high reduction of the reporter activity. In S. cerevisiae histone H3 terminal tails assay, the H3 acetylation levels were highly reduced by treatment with 0.6-1 mM 9, while 18 was effective only at 1.5 mM. In human leukemia U937 cell line, at 1 mM 9 and 18 showed effects on cell cycle (arrest in G1 phase, 9), apoptosis (9), and granulocytic differentiation (18). When tested on U937 cell nuclear extracts to evaluate their histone acetyltransferase (HAT) inhibitory action, both compounds were able to reduce the enzyme activity when used at 500 μM. Another quinoline, compound 22, was synthesized with the aim to improve the activity observed with 9 and 18. Tested in the HAT assay, 22 was able to reduce the HAT catalytic action at 50 and 25 μM, thereby being comparable to anacardic acid, curcumin, and MB-3 used as references. Finally, in U937 cells, compounds 9 and 18 used at 2.5 mM were able to reduce the extent of the acetylation levels of histone H3 (9) and α-tubulin (9 and 18). In the same assay, 22 at lower concentration (100 μM) showed the same hypoacetylating effects with both histone and non-histone substrates.